Radium-223, enzalutamide, and a bone-protecting agent may be a new treatment option for mCRPC patients with bone metastases, according to Silke Gillessen, MD.

Delcath Systems, Inc. , an interventional oncology company focused on the treatment of primary and metastatic liver cancers, today announced that the U.S. Food and Drug Administration (FDA) has ...

Elacestrant, a selective estrogen receptor degrader, demonstrated significant improvements in progression-free survival (PFS) ...

Truqap combination showed a statistically and clinically meaningful improvement in radiographic progression-free survival for ...

According to the International Agency for Research on Cancer, there were 64,611 new cases and 57,727 deaths in India alone in 2022. The incidence of stomach cancer has been rising, with over 40% of ...